secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004190
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero reports preliminary cash of ~$109M as of Dec 31, 2022; updates investor presentation
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities of ~$109M as of Dec 31, 2022 (unaudited, subject to change).
- Updated investor presentation highlights SPR720 as a potential first-line oral therapy for NTM infections.
- Partnerships for tebipenem HBr and SPR206 are noted to support a strong balance sheet.
- Audited FY2022 financials are not yet available; preliminary estimate may differ materially.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523004190/0001193125-23-004190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523004190/d411727d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer